Tags

Type your tag names separated by a space and hit enter

Rotavirus vaccines: entering a new stage of deployment.
Curr Opin Infect Dis. 2007 Oct; 20(5):501-7.CO

Abstract

PURPOSE OF REVIEW

Rotavirus is the single most important cause of severe diarrhoea in infants and young children. This review provides updated information concerning three rotavirus vaccines that are being evaluated and introduced globally.

RECENT FINDINGS

Two large, phase III clinical trials, each involving more than 60,000 infants in both developing and developed countries, demonstrated that both RotaTeq (Merck & Co., Whitehouse Station, New Jersey, USA), the pentavalent human-bovine reassortant vaccine, and Rotarix (GlaxoSmithKine Biologicals, Rixensart, Belgium), the monovalent live-attenuated human rotavirus vaccine, are safe with respect to intussusception when the first dose is administered between 6 and 12 weeks of age, and that both vaccines are 90-95% efficacious in preventing severe rotavirus gastroenteritis including hospitalization. The bovine (UK)-human rotavirus reassortant tetravalent (BRV-TV) vaccine, developed at the National Institutes of Health (USA), was licensed for local production in several developing countries.

SUMMARY

Rotavirus vaccines are entering a new stage of deployment toward the goal of reducing morbidity and mortality attributed to rotavirus infection in developing countries, and hospitalizations and emergency visits caused by rotavirus in developed countries. High vaccine prices appear to offset cost savings, and may make policymakers even in wealthy countries hesitate to introduce a rotavirus vaccine into their childhood immunization programmes.

Authors+Show Affiliations

Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan. onakagom@net.nagasaki-u.ac.jpNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17762784

Citation

Nakagomi, Osamu, and Nigel A. Cunliffe. "Rotavirus Vaccines: Entering a New Stage of Deployment." Current Opinion in Infectious Diseases, vol. 20, no. 5, 2007, pp. 501-7.
Nakagomi O, Cunliffe NA. Rotavirus vaccines: entering a new stage of deployment. Curr Opin Infect Dis. 2007;20(5):501-7.
Nakagomi, O., & Cunliffe, N. A. (2007). Rotavirus vaccines: entering a new stage of deployment. Current Opinion in Infectious Diseases, 20(5), 501-7.
Nakagomi O, Cunliffe NA. Rotavirus Vaccines: Entering a New Stage of Deployment. Curr Opin Infect Dis. 2007;20(5):501-7. PubMed PMID: 17762784.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rotavirus vaccines: entering a new stage of deployment. AU - Nakagomi,Osamu, AU - Cunliffe,Nigel A, PY - 2007/9/1/pubmed PY - 2007/12/11/medline PY - 2007/9/1/entrez SP - 501 EP - 7 JF - Current opinion in infectious diseases JO - Curr. Opin. Infect. Dis. VL - 20 IS - 5 N2 - PURPOSE OF REVIEW: Rotavirus is the single most important cause of severe diarrhoea in infants and young children. This review provides updated information concerning three rotavirus vaccines that are being evaluated and introduced globally. RECENT FINDINGS: Two large, phase III clinical trials, each involving more than 60,000 infants in both developing and developed countries, demonstrated that both RotaTeq (Merck & Co., Whitehouse Station, New Jersey, USA), the pentavalent human-bovine reassortant vaccine, and Rotarix (GlaxoSmithKine Biologicals, Rixensart, Belgium), the monovalent live-attenuated human rotavirus vaccine, are safe with respect to intussusception when the first dose is administered between 6 and 12 weeks of age, and that both vaccines are 90-95% efficacious in preventing severe rotavirus gastroenteritis including hospitalization. The bovine (UK)-human rotavirus reassortant tetravalent (BRV-TV) vaccine, developed at the National Institutes of Health (USA), was licensed for local production in several developing countries. SUMMARY: Rotavirus vaccines are entering a new stage of deployment toward the goal of reducing morbidity and mortality attributed to rotavirus infection in developing countries, and hospitalizations and emergency visits caused by rotavirus in developed countries. High vaccine prices appear to offset cost savings, and may make policymakers even in wealthy countries hesitate to introduce a rotavirus vaccine into their childhood immunization programmes. SN - 0951-7375 UR - https://www.unboundmedicine.com/medline/citation/17762784/Rotavirus_vaccines:_entering_a_new_stage_of_deployment_ L2 - http://dx.doi.org/10.1097/QCO.0b013e3282a56ba0 DB - PRIME DP - Unbound Medicine ER -